Meeting
2013 ASCO Annual Meeting
Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network.
Authors
Kathryn S. Kolibaba
Compass Oncology, Vancouver, WA
Kathryn S. Kolibaba , Hsing-wen Chung , Rahul Dhanda , Debra Rembert , Stephanie Lustgarten , Jing L. Marantz , Hui Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7065)
DOI
10.1200/jco.2013.31.15_suppl.7065
Abstract #
7065
Poster Bd #
38A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).
First Author: Lei Chen
First Author: Ronald J. Rieder
Poster
2023 ASCO Annual Meeting
Report of a chronic myeloid leukemia registry in a low-and middle-income setting.
First Author: Nicolas Anthony Othieno-Abinya
Poster
2020 ASCO Virtual Scientific Program
Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.
First Author: Ehab L. Atallah